Population study of triazolam pharmacokinetics. 1986

H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader

The kinetics of a single 0.5 mg oral dose of the triazolobenzodiazepine hypnotic triazolam, were studied in 54 healthy young men aged 20-44 years, with a mean body weight of 77 kg. Triazolam kinetics were determined from multiple plasma concentrations measured during 14 h post-dose. The overall mean +/- s.e. mean (with range) kinetic variables were: peak plasma concentration, 4.4 +/- 0.3 (1.7-9.4) ng ml-1; time of peak, 1.3 +/- 0.1 (0.5-4.0) h after dose; elimination half-life, 2.6 +/- 0.1 (1.1-4.4) h; total AUC: 19.1 +/- 1.1 (4.4-47.7) ng ml-1 h; oral clearance, 526 +/- 38 (175-1892) ml min-1. All kinetic variables were consistent with Poisson distributions, based on the Kolmogorov-Smirnov Goodness of Fit test. None of the variables fit normal distributions. Four of five were consistent with a log normal distribution. Peak plasma level was highly correlated with clearance (r = -0.85, P less than 0.0001), and AUC (r = 0.85, P less than 0.0001) but not with body weight (r = 0.21, NS). Clearance and body weight were not correlated (r = -0.01). Triazolam clearance may vary widely even within a homogeneous group of healthy young men.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013223 Statistics as Topic Works about the science and art of collecting, summarizing, and analyzing data that are subject to random variation. Area Analysis,Estimation Technics,Estimation Techniques,Indirect Estimation Technics,Indirect Estimation Techniques,Multiple Classification Analysis,Service Statistics,Statistical Study,Statistics, Service,Tables and Charts as Topic,Analyses, Area,Analyses, Multiple Classification,Area Analyses,Classification Analyses, Multiple,Classification Analysis, Multiple,Estimation Technic, Indirect,Estimation Technics, Indirect,Estimation Technique,Estimation Technique, Indirect,Estimation Techniques, Indirect,Indirect Estimation Technic,Indirect Estimation Technique,Multiple Classification Analyses,Statistical Studies,Studies, Statistical,Study, Statistical,Technic, Indirect Estimation,Technics, Estimation,Technics, Indirect Estimation,Technique, Estimation,Technique, Indirect Estimation,Techniques, Estimation,Techniques, Indirect Estimation
D014229 Triazolam A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Apo-Triazo,Gen-Triazolam,Halcion,Trilam,U-33,030,Apo Triazo,Gen Triazolam,U 33,030,U33,030

Related Publications

H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader
January 1983, European journal of clinical pharmacology,
H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader
June 1997, Journal of clinical psychopharmacology,
H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader
December 1993, Clinical pharmacology and therapeutics,
H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader
September 1998, Pharmacology & toxicology,
H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader
June 1987, British journal of clinical pharmacology,
H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader
August 1995, Journal of clinical psychopharmacology,
H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader
January 1990, International journal of clinical pharmacology research,
H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader
January 1983, British journal of clinical pharmacology,
H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader
January 2015, Biological & pharmaceutical bulletin,
H Friedman, and D J Greenblatt, and E S Burstein, and J S Harmatz, and R I Shader
May 1997, International clinical psychopharmacology,
Copied contents to your clipboard!